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all 9 patients received rituximab at 2-18 days (4-6 doses)
after diagnosis. Early rituximab ( 7 days) reduced time to
CR (Hb  8 &/or platelets  100): median 13 days (7-49
days) if early rituximab in 4 patients versus 58 days (19-98
days) in 5 without early rituximab. Moreover, an initial
IVIg/corticosteroids/rituximab combination was best (CR 7-
13 days). Four patients ﬂared at 28-393 days but all
achieved CR with further treatment. Drug therapy was well
tolerated whereas 2 of 3 patients who underwent
splenectomy with initial therapy or with relapse had
complications. Eight of 9 AH/ITP patients are alive &
disease free. Seven of them are in CR from AH/ITP at a
median of 30 months (range 9-102) follow-up after AH/ITP
diagnosis whereas one has recurrent AH requiring therapy.
Conclusions: While AH/ITP is infrequent it can have sudden
onset and be life-threatening. The mechanism is likely
transient B-cell immune dysregulation during immunosup-
pression taper, and thus patient monitoring and prompt
recognition during this period are warranted. Early
rituximab treatment is both mandated at presentation in
severe disease and will likely reduce corticosteroid exposure
& could avoid splenectomy.334
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Background: Reactivation of cytomegalovirus (CMV) and
Epstein-Barr virus (EBV) following allogeneic stem cell
transplant occurs in 60-70% and 5-15% of patients
respectively. CMV disease can present as pancytopenia,
disordered liver function, pneumonitis, retinitis or
neurological disorders. EBV reactivation can result in post
transplant lymphoproliferative disorder (PTLD). At risk
patients are monitored using DNA PCR assays and
pre-emptive therapy commenced. The optimum timing for
intervention has not been established.
Methods: We identiﬁed at-risk patients receiving an
allogeneic transplant during the period 2012-2013 from ourinstitutional database and retrospectively collected data
from the electronic and paper records.
Results: Complete data was available for 27 patients. The
diagnoses were AML/MDS (14), ALL (6), CLL (3), CML (1),
aplastic anaemia (1) andmyeloﬁbrosis (1). 26 were at risk for
EBV reactivation and 13 were at risk for CMV reactivation.
5/13 (38%) patients developed CMV reactivation at a median
of 26 days post transplant (range 22-49). The median CMV
DNA peak titre was 3647 IU/ml (range 603-62616). 4/5
patients were treated with valganciclovir and none
developed CMV disease. Valganciclovir was well tolerated
and effective in all cases. 7/26 patients (27%) developed EBV
reactivation after amedian 60 days (range 10-221). 2 patients
(12.5%) developed lymphadenopathy and received rituximab
with a complete response. Two patients developed late onset
recurrent EBV reactivation following treatment with
rituximab. One patient had a rising titre from day +165,
continuing to rise from <137 to 37944 IU/ml on day +494.
The second patient reactivated on day +225 with a titre
continuing to rise to 23693 IU/ml on day +264. Neither
patient was on immunosuppression or has developed clinical
or radiological evidence of PTLD.
Conclusion: CMV reactivation was less frequent than
previously reported and pre-emptive therapy was effective.
It is possible that some patients were treated unnecessarily
although treatment was well tolerated. EBV reactivation
rates were consistent with those previously reported. Two
cases of PTLD highlight the importance of regular EBV titre
monitoring and early treatment. The late re-emergence
of EBV reactivation in patients who are not on immuno-
suppression is not well described in the literature and its
pathogenesis and clinical signiﬁcance may be different from
early reactivation.335
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Micafungin Anti-Fungal Prophylaxis in Pediatric
Patients Undergoing Hematopoietic Cell Transplantation
(HCT) - Can We Give Higher Dose, Less Frequently? - a
Pharmacokinetic (PK) Study
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Background: Disseminated fungal infection is a major cause
of morbidity and mortality in children undergoing HCT.
Anti-fungal prophylaxis with intravenous micafungin has a
distinct advantage over amphotericin-B and oral triazoles
due to its better safety proﬁle, speciﬁcally in terms of hepatic
and renal toxicity, and lack of drug-drug interactions
